BioWa, Inc has a patented technology platform called Potelligent which modifies monoclonal antibodies so that they have enhanced binding to increase Antibodyterm-dependent cellular cytotoxicity (ADCC). ADCC is the mechanism by which some antibodies can kill cancer cells. Once an antibody binds to a cell, Natural Killer (NK) cells and Monocytes in the immune system attack the bound cell, ultimately killing it.

    UCB biopharmaceutical company has been has been allowed to use Potelligent in order to develop new antibodies toward novel targets. The enhanced ADCC could help bring new antibodies to market that have greater efficacy while possibly lowering production costs of the treatment. Erbituxterm and Herceptin are antibodies whose efficacy is dependent on ADCC.